VEGF receptor signalling ? in control of vascular function

By A. Olsson, A. Dimberg, J. Kreuger, L. Claesson‐Welsh. Nature reviews. Molecular cell biology, 2006

3,245 citations recorded by the source corpus.

View Paper: https://www.semanticscholar.org/paper/8b7af5c6715f099c217b08f15b1e35a577f4c2ae

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Molecular Biology

In Oncology

Citations in the corpus

Diabetic macular edema: pathogenesis and treatment. (2009, background): “As noted previously, VEGF-A is a major mediator of increased retinal permeability.(142,256) Blockage of VEGF has shown to reduce vascular permeability.”
Differential Roles of Macrophages in Diverse Phases of Skin Repair (2010, background): “To identify factors that might mediate the accelerated vascular response and the myofibroblast differentiation in control mice, we stained wound tissue for TGF-b1, a signature mediator of myofibroblast differentiation (23), and VEGF-A, one of the most potent angiogenic mediators (24).”
Vascular endothelial growth factor (VEGF) signaling in tumor progression. (2007, background): “Inactivating mutations in the catalytic loop of the kinase domain of VEGFR3 lead to human hereditary lymphedema (Milroy’s disease) that is characterized by a chronic and disfiguring swelling of the extremities owing to defective cutaneous lymphatic vessels; VEGFR3 is the only VEGF receptor for which”
Ten years of anti-vascular endothelial growth factor therapy (2016, background): “VEGFR1 is also expressed by monocytes and macrophages as well as in tumour cells 27 , and VEGFR3 is mainly present in lymphatic endothelial cells, where it regulates lymphangiogenesis 28 .”
Molecular basis of the inner blood-retinal barrier and its breakdown in diabetic macular edema and other pathological conditions. (2013, background): “VEGFR2 signaling depending on the tissue context (Bruns et al., 2009; Olsson et al., 2006).”
VEGF in Signaling and Disease: Beyond Discovery and Development (2019, background): “NRP-2 performs a similar role in regulating lymphangiogenesis through its interactions with VEGFR3 (adapted from Ferrara and Adamis, 2016).”
Vascular endothelial growth factor (VEGF) - key factor in normal and pathological angiogenesis. (2018, background): “VEGFR-3 has an affinity for VEGF-C and VEGF-D [3, 13, 33].”
MiRNA-Directed Regulation of VEGF and Other Angiogenic Factors under Hypoxia (2006, background): “When under hypoxia stimulation, VEGF is not the only angiogenic gene up-regulated, as other angiogenic factors have been reported to be up-regulated as well [22,23].”
Alternative pre-mRNA splicing regulation in cancer: pathways and programs unhinged. (2010, background): “How does what appears to be a minor modification in VEGF result in such drastically different properties? The canonical form of VEGFA binds to VEGF receptor 1 (VEGFR1) or VEGFR2, as well as coreceptors neurophilin 1 (NRP1) and heparan sulfate proteoglycan (HSPG) (Olsson et al. 2006).”
Lymphangiogenesis: Molecular mechanisms and future promise. (2010, background): “VEGFR-3 can form heterodimers with VEGFR-2 upon binding of the mature, proteolytically processed forms of VEGF-C and VEGF-D, which may lead to unique combinatorial signals by the intracellular domains of the two receptors (Olsson et al., 2006) (Figure 3).”